scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0041-1345(98)00244-9 |
P698 | PubMed publication ID | 9636522 |
P2093 | author name string | R Mendez | |
P2860 | cites work | Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group | Q28247583 |
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group | Q41439111 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multicenter clinical trial | Q6934595 |
P304 | page(s) | 1287-1289 | |
P577 | publication date | 1998-06-01 | |
P1433 | published in | Transplantation Proceedings | Q7834825 |
P1476 | title | FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group | |
P478 | volume | 30 |
Q43101009 | Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis |
Q34181796 | Current treatment practice in immunosuppression |
Q73214564 | Dosing and management guidelines for tacrolimus in renal transplant patients |
Q73219494 | Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period |
Q24187213 | Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients |
Q37587317 | TAC-TIC use of tacrolimus-based regimens in lupus nephritis |
Q44577551 | Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine |
Q73214574 | The Benelux experience with the combination of tacrolimus and mycophenolate mofetil |
Q33957200 | The use of mycophenolate mofetil in transplant recipients |
Q33806707 | Use of tacrolimus in renal transplantation |
Search more.